Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

455.31 +1.76 (+0.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 Next >
3 Small Financial Software Makers Showing Strong Chart Action
Financial software firms Intapp, Vertex, and GuidewIre are headed toward greater profitability and also boast strong chart action. 
Via MarketBeat
Bullish News May Push Vertex Pharmaceuticals Above 52-Week High
A recent announcement by Vertex Pharmaceuticals is confirming a technical signal that could allow the stock to make a new run at its 52-week high 
Via MarketBeat
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
Vertex to Participate in Upcoming Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Reports Third Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Announce Third Quarter 2022 Financial Results on October 27
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Shares Higher On Optimism About CRISPR Partnership
Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments. 
Via MarketBeat
Exposures Product Safety
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Appoints Jonathan Biller as Chief Legal Officer
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative... 
Via TheNewswire.com
Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Reports Second Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Advances VX-548 in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Announce Second Quarter 2022 Financial Results on August 4
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.